Air Force Military Medical University, China is the lead sponsor of 20 current clinical trials in our China register. 16 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Fecal Microbiota Transplantation, Rifaximin、Lactulose and Adebrelimab. The most-studied condition is Gastroesophageal Varices Bleeding.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
NCT05510323 · Glomerulonephritis, IGA
Drugs: Cyclophosphamide, Prednisolone |
Phase 3 | Recruiting | 2024-02 | China |
|
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318 · ClinicalTrials.gov ↗ · Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
Drug: NSAIDs |
Not applicable | Recruiting | 2025-07 | China |
|
Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis
NCT07253389 · ClinicalTrials.gov ↗ · Liver Cirrhosis, Gastroesophageal Varices Bleeding
|
Not applicable | Recruiting | 2025-10 | China |
|
Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma
NCT07610551 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
|
Observational | Recruiting | 2022-02 | China |
|
The Effect of Aspirin on Recurrent Acute Pancreatitis
NCT06185621 · ClinicalTrials.gov ↗ · Recurrent Acute Pancreatitis, Prevention, Aspirin
Drug: Aspirin |
Not applicable | Recruiting | 2023-11 | China |
|
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
NCT07569679 · ClinicalTrials.gov ↗ · Biliary Tract Cancer
|
Phase 2 | Recruiting | 2025-12 | China |
|
Frequency of Electrical Acupoint Stimulation on Hypotension in TAVR Patients
NCT07365345 · ClinicalTrials.gov ↗ · Transcatheter Aortic Valve Replacement (TAVR), Hemodynamic Stability, Anesthesia Induction
|
Not applicable | Recruiting | 2026-01 | China |
|
Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome
NCT06722534 · ClinicalTrials.gov ↗ · Peutz-Jeghers Syndrome, Celecoxib, Small Bowel Polyp
|
Not applicable | Recruiting | 2025-02 | China |
|
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441 · ClinicalTrials.gov ↗ · ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID)
|
Not applicable | Recruiting | 2025-06 | China |
|
The Clinical Course and Factors for the Progression of Uninvestigated Dyspepsia to Functional Dyspepsia
NCT05823636 · ClinicalTrials.gov ↗ · Dyspepsia
|
Observational | Recruiting | 2023-01 | China |
|
Efficacy and Safety of Variceal Embolization Combined With Partial Splenic Artery Embolization for Variceal Bleeding in Cavernous Transformation of Portal Vein.
NCT07310316 · ClinicalTrials.gov ↗ · Cavernous Transformation of Portal Vein, Gastroesophageal Varices Bleeding
|
Not applicable | Recruiting | 2026-01 | China |
|
Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery
NCT07683936 · ClinicalTrials.gov ↗ · Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS
|
Phase EARLY_PHASE1 | Recruiting | 2026-06 | China |
|
Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPS
NCT07799948 · ClinicalTrials.gov ↗ · Hepatic Encephalopathy, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Portal Hypertension
|
Not applicable | Recruiting | 2026-09 | China |
|
GNT Induction Treatment in Locally Advanced NPC
NCT06026878 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
Drug: Gemcitabine/Cisplatin |
Phase 3 | Recruiting | 2023-09 | China |
|
Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
NCT06756139 · ClinicalTrials.gov ↗ · Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug
|
Not applicable | Recruiting | 2024-11 | China |
|
Factors for Prolonged Hospital Stays in Patients Undergoing ERCP
NCT07568626 · ClinicalTrials.gov ↗ · Post-ERCP Adverse Events, ERCP Complications
|
Observational | Recruiting | 2026-02 | China |
|
Mesenteric Vein Access for OPVT-Related Recurrent Variceal Bleeding: An Ambispective Cohort
NCT07666256 · Occlusive Portal Vein Thrombosis (OPVT), Cavernous Transformation of Portal Vein, Gastroesophageal Varices Bleeding
|
Not applicable | Not yet open | 2026-07 | China |
|
Evaluation of the Outcome of Fecal Microbiota Transplantation
NCT07454408 · ClinicalTrials.gov ↗ · Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS
|
Phase 1/2 | Not yet open | 2026-03 | China |
|
Endoscopic vs Non-endoscopic Drainage for Benign Gallbladder Diseases in High-risk Patients or Patients Desiring Gallbladder Preservation
NCT07649811 · ClinicalTrials.gov ↗ · Gallbladder Diseases, Cholecystitis, Acute, Cholelithiasis
|
Observational | Not yet open | 2026-07 | China |
|
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
NCT07535138 · ClinicalTrials.gov ↗ · Membranous Nephropathy, Lupus Nephritis (LN), IgA Nephropathy (IgAN)
|
Phase EARLY_PHASE1 | Not yet open | 2026-05 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 20 | 16 |
A trial with sites in more than one country appears in each of those registers.
Air Force Military Medical University, China is the lead sponsor of 20 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 16 of its 20 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 11 drugs and biologicals as interventions. The most frequent are Fecal Microbiota Transplantation (2), Rifaximin、Lactulose (2), Adebrelimab (1), Apatinib (1) and Aspirin (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.